Primary, Secondary Progressive MS Therapy to be Tested in Phase 2 Trial by MediciNova

Stuart SchlossmanMS Research Study and Reports, SPMS-PPMS News

primary and secondary MS trialMediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in progressive multiple sclerosis patients. As of September 15th, 150 of an expected 250 patients have enrolled for treatment, and the trial is on track to complete enrollment by the second quarter of 2015.
“We are very pleased to have completed 60% of the enrollment in this study,” said Yuichi Iwaki, MD, PhD, Presiden and CEO of MediciNova, in a news release. “We look forward to providing further updates as the study progresses.”
The study is headed by Robert Fox, MD, MS, FAAN, Vice-Chair for Research if the Neurological Institute of the Cleveland Clinic. NeuroNEXT clinical trial network is conducting the study at 28 academic medical centers, and funding is provided by the National Institutes of Health.

~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT and up to date, 
Sign-Up for our email
.

WATCH OUR Multiple Sclerosis recorded
 EDUCATIONAL VIDEOS by Topic: 

.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews